Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

December 30, 2025

Conditions
Upper Gastrointestinal Bleeding (UGIB)Variceal BleedingCirrhosis
Interventions
DRUG

Tranexamic Acid and vitamin K

"Tranxemic acid (1 g loading dose followed by 3 g maintenance dose over 24- 48 hours) and intravenous injection (10 mg daily of vitamin K for 24-48 h) along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."

DRUG

Placebo

"Intravenous saline over 24-48 hours along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."

Trial Locations (1)

31516

RECRUITING

Tanta University Hospitals, Tanta

All Listed Sponsors
lead

Tanta University

OTHER